Biblio
Found 20 results
Filters: Keyword is Animals and Author is Porreca, Frank [Clear All Filters]
Cyclic non-opioid dynorphin A analogues for the bradykinin receptors.. Bioorg Med Chem Lett. 26(22):5513-5516.
.
2016. Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor.. J Med Chem. 59(22):10291-10298.
.
2016. Various modifications of the amphipathic dynorphin A pharmacophore for rat brain bradykinin receptors.. Chem Biol Drug Des. 88(4):615-9.
.
2016. Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.. Bioorg Med Chem Lett. 25(20):4683-8.
.
2015. Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.. Bioorg Med Chem. 23(18):6185-94.
.
2015. Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.. J Med Chem. 58(21):8573-83.
.
2015. Modification of amphipathic non-opioid dynorphin A analogues for rat brain bradykinin receptors.. Bioorg Med Chem Lett. 25(1):30-3.
.
2015. Neuropathic plasticity in the opioid and non-opioid actions of dynorphin A fragments and their interactions with bradykinin B2 receptors on neuronal activity in the rat spinal cord.. Neuropharmacology. 85:375-83.
.
2014. Structure-activity relationships of non-opioid [des-Arg(7)]-dynorphin A analogues for bradykinin receptors.. Bioorg Med Chem Lett. 24(21):4976-9.
.
2014. Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.. J Bone Miner Res. 28(1):92-107.
.
2013. Effect of anchoring 4-anilidopiperidines to opioid peptides.. Bioorg Med Chem Lett. 23(11):3434-7.
.
2013. Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.. Bioorg Med Chem Lett. 23(17):4975-8.
.
2013. Mechanisms of Bv8-induced biphasic hyperalgesia: increased excitatory transmitter release and expression.. Neurosci Lett. 521(1):40-5.
.
2012. Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.. Bioorg Med Chem Lett. 22(12):4153-8.
.
2012. Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.
.
2011. Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.
.
2011. .
2011. Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.. Brain Res. 1395:1-11.
.
2011. Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.. Bioorg Med Chem. 19(20):6135-42.
.
2011. Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.. Eur J Pharmacol. 583(1):62-72.
.
2008.